The use of antibiotics in the intensive care unit of a tertiary hospital in Malawi.
Africa
Antibiotic resistance
Antibiotics
ICU
Malawi
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
19 Oct 2020
19 Oct 2020
Historique:
received:
22
04
2020
accepted:
12
10
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
29
10
2020
Statut:
epublish
Résumé
Antibiotic resistance is on the rise. A contributing factor to antibiotic resistance is the misuse of antibiotics in hospitals. The current use of antibiotics in ICUs in Malawi is not well documented and there are no national guidelines for the use of antibiotics in ICUs. The aim of the study was to describe the use of antibiotics in a Malawian ICU. A retrospective review of medical records of all admissions to the main ICU in Queen Elizabeth Central Hospital in Blantyre, Malawi, between January 2017 and April 2019. Data were extracted from the ICU patient register on clinical parameters on admission, diagnoses, demographics and antibiotics both prescribed and given for all patients admitted to the ICU. Usage of antibiotics in the ICU and bacterial culture results from samples taken in the ICU and in the peri-ICU period, (from 5 days before ICU admission to 5 days after ICU discharge), were described. Six hundred-and-forty patients had data available on prescribed and received medications and were included in the analyses. Of these, 577 (90.2%) were prescribed, and 522 (81.6%) received an antibiotic in ICU. The most commonly used antibiotics were ceftriaxone, given to 470 (73.4%) of the patients and metronidazole to 354 (55.3%). Three-hundred-and-thirty-three (52.0%) of the patients received more than one type of antibiotic concurrently - ceftriaxone and metronidazole was the most common combination, given to 317 patients. Forty five patients (7.0%) were given different antibiotics sequentially. One-hundred-and-thirty-seven patients (21.4%) had a blood culture done in the peri-ICU period, of which 70 (11.0% of the patients) were done in the ICU. Twenty-five (18.3%) of the peri-ICU cultures were positive and eleven different types of bacteria were grown in the cultures, of which 17.2% were sensitive to ceftriaxone. We have found a substantial usage of antibiotics in an ICU in Malawi. Ceftriaxone, the last-line antibiotic in the national treatment guidelines, is commonly used, and bacteria appear to show high levels of resistance to it, although blood culture testing is infrequently used. Structured antibiotic stewardship programs may be useful in all ICUs.
Sections du résumé
BACKGROUND
BACKGROUND
Antibiotic resistance is on the rise. A contributing factor to antibiotic resistance is the misuse of antibiotics in hospitals. The current use of antibiotics in ICUs in Malawi is not well documented and there are no national guidelines for the use of antibiotics in ICUs. The aim of the study was to describe the use of antibiotics in a Malawian ICU.
METHODS
METHODS
A retrospective review of medical records of all admissions to the main ICU in Queen Elizabeth Central Hospital in Blantyre, Malawi, between January 2017 and April 2019. Data were extracted from the ICU patient register on clinical parameters on admission, diagnoses, demographics and antibiotics both prescribed and given for all patients admitted to the ICU. Usage of antibiotics in the ICU and bacterial culture results from samples taken in the ICU and in the peri-ICU period, (from 5 days before ICU admission to 5 days after ICU discharge), were described.
RESULTS
RESULTS
Six hundred-and-forty patients had data available on prescribed and received medications and were included in the analyses. Of these, 577 (90.2%) were prescribed, and 522 (81.6%) received an antibiotic in ICU. The most commonly used antibiotics were ceftriaxone, given to 470 (73.4%) of the patients and metronidazole to 354 (55.3%). Three-hundred-and-thirty-three (52.0%) of the patients received more than one type of antibiotic concurrently - ceftriaxone and metronidazole was the most common combination, given to 317 patients. Forty five patients (7.0%) were given different antibiotics sequentially. One-hundred-and-thirty-seven patients (21.4%) had a blood culture done in the peri-ICU period, of which 70 (11.0% of the patients) were done in the ICU. Twenty-five (18.3%) of the peri-ICU cultures were positive and eleven different types of bacteria were grown in the cultures, of which 17.2% were sensitive to ceftriaxone.
CONCLUSION
CONCLUSIONS
We have found a substantial usage of antibiotics in an ICU in Malawi. Ceftriaxone, the last-line antibiotic in the national treatment guidelines, is commonly used, and bacteria appear to show high levels of resistance to it, although blood culture testing is infrequently used. Structured antibiotic stewardship programs may be useful in all ICUs.
Identifiants
pubmed: 33076857
doi: 10.1186/s12879-020-05505-6
pii: 10.1186/s12879-020-05505-6
pmc: PMC7574463
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ceftriaxone
75J73V1629
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
776Subventions
Organisme : Life Support Foundation
ID : Not applicable
Organisme : Association of Anesthetists
ID : Not applicable
Références
PLoS Med. 2011 Oct;8(10):e1001104
pubmed: 22022233
J Intensive Care Med. 2018 Dec;33(12):647-655
pubmed: 29534630
Antimicrob Resist Infect Control. 2013 Nov 18;2:31
pubmed: 24237856
Intensive Care Med. 2017 Sep;43(9):1187-1197
pubmed: 28160023
Indian J Crit Care Med. 2018 Jun;22(6):422-426
pubmed: 29962742
Emerg Med Clin North Am. 2017 Feb;35(1):25-42
pubmed: 27908336
Clin Infect Dis. 2012 Sep;55(6):807-15
pubmed: 22700828
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S124-9
pubmed: 11524708
Clin Infect Dis. 1993 Nov;17 Suppl 2:S346-51
pubmed: 8274599
Intensive Care Med. 2016 Jun;42(6):955-8
pubmed: 27043234
BMC Health Serv Res. 2019 Jan 23;19(1):64
pubmed: 30674316
Einstein (Sao Paulo). 2015 Jul-Sep;13(3):448-53
pubmed: 26132360
World J Crit Care Med. 2015 Feb 04;4(1):13-28
pubmed: 25685719
Dtsch Arztebl Int. 2017 Dec 15;114(50):858-865
pubmed: 29271345
Crit Care. 2014 Aug 13;18(5):480
pubmed: 25405992
Ann Intern Med. 2016 Sep 6;165(5):363-72
pubmed: 27239977
BMC Infect Dis. 2017 May 22;17(1):358
pubmed: 28532467
Lancet Infect Dis. 2017 Oct;17(10):1042-1052
pubmed: 28818544
Drug Resist Updat. 2000 Oct;3(5):303-311
pubmed: 11498398
BMC Pediatr. 2018 Dec 20;18(1):391
pubmed: 30572851
Intensive Care Med. 2018 Feb;44(2):189-196
pubmed: 29288367
J Clin Pharm Ther. 2017 Oct;42(5):579-584
pubmed: 28485087
Pan Afr Med J. 2017 Feb 02;26:60
pubmed: 28451037
Malawi Med J. 2017 Sep;29(3):268-271
pubmed: 29872519